Skip to content
HowShorted

PTC Therapeutics, Inc. short interest in 2022

In 2022, PTC Therapeutics, Inc.'s disclosed short interest ran from 8.94% of shares outstanding on 14 Jan 2022 to 7.21% on 30 Dec 2022, a change of -1.73 percentage points. The year's high was 8.94% on 14 Jan 2022 and its low 6.26% on 30 Nov 2022, averaging 7.36% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.91 days on 31 Mar 2022. Full history: PTC Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PTC Therapeutics, Inc. in 2022

2022 in figures

Start of year
8.94% (14 Jan 2022)
End of year
7.21% (30 Dec 2022)
Change
-1.73 pp
High
8.94% (14 Jan 2022)
Low
6.26% (30 Nov 2022)
Average
7.36%
Highest days to cover
12.91 (31 Mar 2022)
SEC filings marked
9

Every report in 2022

PTC Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.94%4.57results (8-K)
31 Jan 20226.99%7.32
15 Feb 20227.39%9.39
28 Feb 20227.61%8.3210-K filed, results (8-K)
15 Mar 20227.61%10.00
31 Mar 20227.60%12.91
14 Apr 20227.93%8.34
29 Apr 20228.56%10.91
13 May 20227.49%7.7310-Q filed, results (8-K)
31 May 20227.62%8.94
15 Jun 20227.88%7.35
30 Jun 20227.07%3.29
15 Jul 20227.90%9.06
29 Jul 20227.26%11.89
15 Aug 20227.17%6.8610-Q filed, results (8-K)
31 Aug 20227.05%9.87
15 Sep 20227.61%8.46
30 Sep 20227.03%8.36
14 Oct 20226.60%11.07
31 Oct 20226.69%5.0110-Q filed, results (8-K)
15 Nov 20226.59%6.66
30 Nov 20226.26%9.17
15 Dec 20226.47%9.48
30 Dec 20227.21%9.52

See also: PTC Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.